The Priority Review

Tag

KRAS G12C

1 story

  1. Clinical trials

    Lilly presents durable first-line activity of olomorasib in KRAS G12C-mutant NSCLC at ESMO 2026

    Lilly reported that olomorasib plus pembrolizumab without chemotherapy achieved durable efficacy, with median progression-free survival not yet reached after a median follow-up of 20.7 months. In a separate rapid oral presentation, the combination with chemoimmunotherapy yielded a 62% investigator-assessed overall response rate and a median duration of response of 14.5 months.